Moreover, use of the small molecule P2X7 antagonist, AZ10606120, which impairs both human and murine P2X7 [36], did not alter GVHD progression in this same humanised mouse model [37], raising the possibility that P2X7 was not involved and that BBG in previous studies [20,21,22] may have acted via another target. Here, P2RX7 is linked to graft versus host disease.